By Owen Hughes
Six imaging networks in England have chosen Annalise.ai as their preferred provider for early lung cancer diagnosis through NHS England’s AI Diagnostic Fund (AIDF).
The £21 million fund, unveiled by NHSE in June 2023, aims to accelerate the adoption of AI and machine learning tools to expedite the diagnosis and treatment of serious illnesses such as cancer, stroke, and heart conditions.
Annalise.ai’s chest X-ray tool will be accessible to radiologists in the Greater Manchester, North East, North Cumbria, Cheshire, Merseyside, East Midlands, Surrey, Sussex, Frimley, and Yorkshire imaging networks following successful tender wins under the AIDF.
The rollout of Annalise.ai’s medical imaging decision support tool, utilizing AI to detect abnormalities in X-rays, is scheduled to be fully operational by November 2024, assisting in the analysis of approximately 2.5 million chest X-rays annually across more than 40 NHS trusts in England.
Dimity Tran, Annalise.ai’s co-founder and deputy CEO, expressed excitement at the nationwide deployment of their solution, which is proven to identify various chest X-ray anomalies and facilitate faster diagnosis of conditions like lung cancer.
Annalise.ai’s tool, implemented in NHS Grampian since 2022, has significantly reduced the interval between chest X-ray assessment and lung cancer treatment while also enhancing early-stage cancer detection rates.
Doncaster and Bassetlaw Teaching Hospitals NHS Foundation Trust and Bradford Teaching Hospitals NHS Foundation Trust have recently announced plans to integrate Annalise.ai within their radiology departments.
